Delirium Tremens (DTs) Treatment & Management
- Author: Michael James Burns, MD, FACEP, FACP; Chief Editor: Michael R Pinsky, MD, CM, Dr(HC), FCCP, MCCM more...
Special concerns in the treatment of alcohol withdrawal include the following:
Failure to consider the diagnosis of alcohol withdrawal syndrome in patients with altered mental status, abnormal vital signs, or single simple seizure
Failure to treat patients with severe alcohol withdrawal syndrome with adequate doses of benzodiazepines, because these patients may require extremely large doses of parenteral benzodiazepines
Making the assumption that all seizures in people with alcoholism are due to alcohol withdrawal without considering other causes of seizures, such as infection, hemorrhage, or trauma
Failure to exclude other etiologies of altered mental status in patients with suspected alcohol withdrawal
Failure to admit patients to the hospital with signs and symptoms of major withdrawal or delirium tremens (DTs)
Failure to diagnose such conditions as hypoglycemia and pancreatitis
Failure to administer thiamine in patients presenting with alcohol withdrawal
Failure to use adequate chemical sedation with use of physical restraints
The administration of a sympatholytic drug (ie, clonidine, beta-blocker), either alone or with inadequate doses of benzodiazepines, can potentially cause problems, because the use of these drugs provides a false sense of security by correcting some of the autonomic manifestations of withdrawal in a patient who may be progressing to DTs. Sympatholytic drugs should not be administered unless adequate doses of benzodiazepines also are administered.
Phenytoin is not effective in preventing or treating alcohol withdrawal seizures. Seizures due to alcohol withdrawal are best prevented and treated with benzodiazepines. A Cochrane systematic review concluded that clinical trials have not shown a benefit for anticonvulsant therapy in treatment of alcohol withdrawal syndrome, but because of the heterogeneity of the trials in interventions and in the assessment of outcomes, definite conclusions about their safety and effectiveness cannot be made.
The use of neuroleptic drugs (phenothiazines, butyrophenones) alone to treat agitation or hallucinations caused by alcohol withdrawal potentially can cause problems, because these drugs are not effective in preventing or treating DTs and may increase the risk of seizures. The administration of a small dose of a butyrophenone, such as haloperidol, may be useful as adjunctive therapy to treat agitation and hallucinations, as long as adequate doses of benzodiazepines have been administered.
The use of alcohol to prevent or treat alcohol withdrawal and DTs is not recommended. Alcohol has multiple toxicities, including pancreatitis, hepatitis, cardiomyopathy, gastritis, and bone marrow suppression. It also has a short half-life and requires monitoring of blood levels when used intravenously, and its use may make it appear to the patient with alcoholism who is beginning recovery that alcohol intake is being condoned. Alcohol treatment has not been shown in controlled trials to be effective in preventing seizures or DTs.
Large amounts of sedatives may be required to achieve adequate control of symptoms. Sometimes, the airway must be controlled to permit the safe administration of adequate doses of sedatives.
Concurrent illnesses such as pneumonia, pancreatitis, hepatitis, and trauma should be identified and treated.
Indications for hospital admission of a patient with alcohol withdrawal syndrome include DTs; severe symptoms, such as hallucinations, disorientation, confusion, autonomic hyperactivity, or extreme agitation; the presence of a medical or surgical condition requiring treatment; a recent history of head injury with loss of consciousness; recurrent seizures; partial seizures; or focal neurologic findings upon examination.
Some authorities advocate the use of a protocolized dose escalation strategy in treating patients with DTs in the ICU. In this strategy, patients with DTs are treated with escalating doses of diazepam with titration of phenobarbital according to the patient's score on the Riker Sedation Agitation Scale (RSAS) (goal 3-4) or the Richmond Agitation Sedation Scale (RASS) (goal 0 to -2). In this approach, diazepam is administered intravenously at escalating doses every 10-15 minutes up to 100-150 mg per dose (or lorazepam IV up to 30 mg per dose) with calculation of the RSAS or RASS after each dose. If the patient reaches the goal, then that dose is used as the maintenance dose. If the goal on the sedation score is not reached, phenobarbital is administered intravenously at repeated doses of 65-260 mg until the desired goal is reached. In retrospective cohort studies, this strategy, compared with a nonprotocolized strategy, appeared to be effective in reducing rates of mechanical ventilation and length of ICU stay. If that fails, then mechanical ventilation and treatment with propofol should be considered. Other drugs to consider when benzodiazepines and phenobarbital are not effective include dexmedetomidine or ketamine. There are no randomized prospective controlled trials of this strategy.[9, 10, 11]
Supportive therapy is an important component of the treatment of alcohol withdrawal syndrome and delirium tremens (DTs). Such therapy includes providing a calm, quiet, well-lit environment; reassurance; ongoing reassessment; attention to fluid and electrolyte deficits; and treatment of any coexisting addictions. Commonly, patients with alcohol withdrawal syndrome have coexisting medical, surgical, and psychiatric conditions that need careful diagnosis and treatment. Multivitamins and folate are frequently administered to these patients, but no evidence exists that vitamins other than thiamine have any benefit in the acute setting.
Administer intravenous (IV) fluids for rehydration, as necessary. Most patients with severe alcohol withdrawal are significantly dehydrated, and their fluid requirements range from 4-10 L in the first 24 hours. Because hypoglycemia is common in these patients due to depleted glycogen stores, a 5% dextrose solution (in 0.90% or 0.45% saline) should be used to prevent hypoglycemia.
Aspiration precautions are often necessary. This may include placing the patient in the left lateral decubitus position or intubating the patient, depending on the patient's level of consciousness. Also, the patient should not be administered any oral medications or fluids.
Monitor and replace electrolytes as necessary, because persons with alcoholism often have low calcium, magnesium, phosphorous, and potassium
Thiamine is useful in preventing Wernicke encephalopathy (confusion, ataxia, ophthalmoplegia) and Wernicke-Korsakoff syndrome. Thiamine has no effect on the symptoms or signs of alcohol withdrawal or on the incidence of seizures or DTs. Routine use of thiamine is recommended because the development of Wernicke encephalopathy or Wernicke-Korsakoff syndrome is disastrous in these patients and can remain unrecognized. Because orally administered thiamine may have poor enteral absorption in alcoholic patients, high-risk patients should receive parenteral thiamine at 100-250 mg once daily for several days. Although it has been a commonly held belief that thiamine must be given before administering glucose to hypoglycemic patients with suspected thiamine deficiency to prevent Wernicke encephalopathy, there is a lack of evidence that this is the case. Current evidence suggests that it is prolonged glucose administration without thiamine supplementation that is a risk factor for the development or worsening of Wernicke encephalopathy. A delay in administering glucose to hypoglycemic patients cannot be recommended, and prompt supplementation with thiamine should be done as soon as feasible.
Persons with alcoholism frequently have large total body deficits of magnesium. Symptoms and signs of magnesium deficiency include hyperactive reflexes, weakness, tremor, refractory hypokalemia, reversible hypoparathyroidism with hypocalcemia, and cardiac dysrhythmias. Serum magnesium levels are often normal in spite of a total body magnesium deficit with significant intracellular magnesium deficiency. Magnesium levels that are initially low may return to normal even though a total body deficiency persists. In animal studies, magnesium deficiency has exacerbated hepatic damage caused by alcohol.
There is insufficient evidence about the benefits or harms of magnesium supplementation to prevent or treat alcohol withdrawal. However, because the administration of magnesium is safe in the absence of renal insufficiency, consider routine administration of magnesium in patients with alcohol withdrawal. In severe deficiency, the deficit is about 1-2 mEq/kg of body weight.
When magnesium is administered intravenously to patients without renal insufficiency, about 50% of the dose is excreted into the urine and not retained by the body. About half of the deficit should be replaced in the first 24 hours. For a 70-kg person with normal renal function, 4-6 g of magnesium sulfate (32-48 mEq of magnesium) is administered by continuous IV infusion on the first day, followed by half that amount daily for 4 days. Alternatively, the same daily dose of magnesium can be administered intramuscularly at 6- to 8-hour intervals. Oral administration of magnesium-containing antacids can be effective but is limited by the development of diarrhea.
As mentioned previously, in critically ill patients in ICUs, symptom-triggered benzodiazepine treatment titrated to the RSAS or RASS, using very-high-dose bolus therapy, with addition of phenobarbital as needed, has been associated with a reduction in the need for mechanical ventilation and possibly a reduced length in the ICU. Fixed-dose regimens often result in excessive sedation or failure to reach the sedation goal.
Intravenous ethanol infusions have been used in the past, especially in surgical ICUs, as prophylaxis against alcohol withdrawal among patients with suspected or proven alcohol dependence. Retrospective, uncontrolled, noncomparative case series have reported the successful and unsuccessful use of IV ethanol in trauma and burn patients.
Comparative or randomized studies have not demonstrated efficacy for this treatment, and this therapy was inferior to diazepam in a prospective, randomized trial. As IV ethanol has a short duration of action; a narrow margin of safety; and toxic effects on the gastric mucosa, pancreas, liver, and bone marrow and on other organs, and requires considerable volumes of fluids for administration, this treatment cannot be recommended.
Using the Revised Clinical Institute for Withdrawal Assessment for Alcohol (CIWA-Ar) scale may not be appropriate for guiding symptom-triggered therapy in patients who have complex medical problems or who are postsurgical, critically ill, or in an ICU. Studies demonstrating the effectiveness of the CIWA-Ar scale in safely managing alcohol withdrawal were performed in medically stable ward patients. Patients with complex medical issues, postsurgical patients, ICU patients, and critically ill patients were generally excluded from these trials. The CIWA-Ar scale has not been validated in these patients. The RSAS or RASS may be preferred in ICU patients.
Moreover, the CIWA-Ar protocol and symptom-triggered therapy have been applied inappropriately to patients who had not been drinking for many weeks and who were not able to communicate, resulting in misdiagnosis and delayed diagnosis of other causes of delirium, as well as severe benzodiazepine intoxication due to inappropriate medication use. Postoperative delirium, for which there are many etiologies, has been misdiagnosed as alcohol withdrawal and the CIWA-Ar applied inappropriately with subsequent mistreatment. Patients with complicated medical and surgical comorbidities are not appropriate candidates for symptom-triggered therapy guided by the CIWA-Ar scale.
The issue of alcohol dependence should be addressed prior to hospital discharge, because detoxification from alcohol in the hospital is not sufficient to prevent a patient’s return to hazardous alcohol use. Treatment to prevent relapse frequently requires extended management over long periods of time. Alcohol cessation programs and support groups, such as Alcoholics Anonymous, should be recommended.
Pharmacologic aids to alcohol cessation should be considered, because they may prevent relapse in patients who have been treated for alcohol dependence. Use of these agents for the long-term treatment of alcohol dependence can be initiated after detoxification to alcohol has been completed. FDA-approved medications used for the treatment of alcoholism include disulfiram, acamprosate, and 2 forms of naltrexone (oral and extended-release injectable). Topiramate, SSRIs, baclofen, and odansetron may also be effective but are not FDA approved. All these agents are, at-best, only modestly effective in the short term.
Cognitive behavioral therapy and motivational enhancement therapy (which are sometimes combined with pharmacologic therapy) have been used successfully to prevent relapse.
Chronic alcoholism is associated with depression as well as anxiety disorder, and the risk of suicide among alcoholics is high. Therefore, persons with alcohol withdrawal should be screened for depression and anxiety disorder after recovery from the alcohol withdrawal state, and they referred to a mental health provider for further assessment and treatment as necessary.
To prevent hazardous alcohol use, routine screening and brief intervention for high-risk alcohol use should be performed in primary care settings and in emergency departments; this may reduce alcohol consumption and adverse consequences in risk drinkers who are not alcohol dependent. Use of the AUDIT or CAGE questionnaire is helpful in screening.
Protocols for screening persons at risk for hazardous alcohol use, followed by a brief intervention (5-10 min) carried out by a clinician, nurse, or social worker, have been shown to result in a reduction in alcohol consumption and alcohol-related injuries and decreased readmissions to the emergency department. Computer-based screening and counseling programs may be useful when clinicians do not have time to perform screening and face-to-face intervention.
The effectiveness of brief interventions for heavier drinkers and in the acute care setting is unknown. Chronic, severe alcohol dependence is frequently resistant to existing methods of interventions, but pharmacotherapy with brief medical management counseling may reduce heavy drinking in these alcohol-dependent persons.[16, 17]
Eyer F, Schuster T, Felgenhauer N, Pfab R, Strubel T, Saugel B. Risk assessment of moderate to severe alcohol withdrawal--predictors for seizures and delirium tremens in the course of withdrawal. Alcohol Alcohol. 2011 Jul-Aug. 46(4):427-33. [Medline].
Kim DW, Kim HK, Bae EK, Park SH, Kim KK. Clinical predictors for delirium tremens in patients with alcohol withdrawal seizures. Am J Emerg Med. 2015 May. 33 (5):701-4. [Medline].
Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 2015 Aug. 72 (8):757-66. [Medline].
Chan GM, Hoffman RS, Gold JA, Whiteman PJ, Goldfrank LR, Nelson LS. Racial variations in the incidence of severe alcohol withdrawal. J Med Toxicol. 2009 Mar. 5(1):8-14. [Medline].
Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989 Nov. 84(11):1353-7. [Medline].
Watling SM, Fleming C, Casey P, Yanos J. Nursing-based protocol for treatment of alcohol withdrawal in the intensive care unit. Am J Crit Care. 1995 Jan. 4(1):66-70. [Medline].
Reoux JP, Oreskovich MR. A comparison of two versions of the clinical institute withdrawal assessment for alcohol: the CIWA-Ar and CIWA-AD. Am J Addict. 2006 Jan-Feb. 15(1):85-93. [Medline].
Khan BA, Guzman O, Campbell NL, Walroth T, Tricker J, Hui SL. Comparison and agreement between the Richmond Agitation-Sedation Scale and the Riker Sedation-Agitation Scale in evaluating patients' eligibility for delirium assessment in the ICU. Chest. 2012 Jul. 142(1):48-54. [Medline].
Gold JA, Rimal B, Nolan A, Nelson LS. A strategy of escalating doses of benzodiazepines and phenobarbital administration reduces the need for mechanical ventilation in delirium tremens. Crit Care Med. 2007 Mar. 35(3):724-30. [Medline]. [Full Text].
Duby JJ, Berry AJ, Ghayyem P, Wilson MD, Cocanour CS. Alcohol withdrawal syndrome in critically ill patients: protocolized versus nonprotocolized management. J Trauma Acute Care Surg. 2014 Dec. 77 (6):938-43. [Medline].
Schmidt KJ, Doshi MR, Holzhausen JM, Natavio A, Cadiz M, Winegardner JE. A Review of the Treatment of Severe Alcohol Withdrawal. Ann Pharmacother. 2016 Feb 9. [Medline].
Krishel S, SaFranek D, Clark RF. Intravenous vitamins for alcoholics in the emergency department: a review. J Emerg Med. 1998 May-Jun. 16(3):419-24. [Medline].
Schabelman E, Kuo D. Glucose before thiamine for Wernicke encephalopathy: a literature review. J Emerg Med. 2012 Apr. 42 (4):488-94. [Medline].
Sarai M, Tejani AM, Chan AH, Kuo IF, Li J. Magnesium for alcohol withdrawal. Cochrane Database Syst Rev. 2013 Jun 5. 6:CD008358. [Medline].
Weinberg JA, Magnotti LJ, Fischer PE, et al. Comparison of intravenous ethanol versus diazepam for alcohol withdrawal prophylaxis in the trauma ICU: results of a randomized trial. J Trauma. 2008 Jan. 64(1):99-104. [Medline].
Friedmann PD. Clinical practice. Alcohol use in adults. N Engl J Med. 2013 Jan 24. 368(4):365-73. [Medline].
Connor JP, Haber PS, Hall WD. Alcohol use disorders. Lancet. 2016 Mar 5. 387 (10022):988-98. [Medline].
Amato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome. Cochrane Database Syst Rev. 2011. (6):CD008537. [Medline].
McCowan C, Marik P. Refractory delirium tremens treated with propofol: a case series. Crit Care Med. 2000 Jun. 28(6):1781-4. [Medline].
Hendey GW, Dery RA, Barnes RL, Snowden B, Mentler P. A prospective, randomized, trial of phenobarbital versus benzodiazepines for acute alcohol withdrawal. Am J Emerg Med. 2011 May. 29(4):382-5. [Medline].
Rosenson J, Clements C, Simon B, Vieaux J, Graffman S, Vahidnia F. Phenobarbital for Acute Alcohol Withdrawal: A Prospective Randomized Double-blind Placebo-controlled Study. J Emerg Med. 2013 Mar. 44(3):592-598.e2. [Medline].
Foster C, Mueller S, Vanderweide L, Kiser T, Fish D, MacLaren R. Addition of dexmedetomidine to the standard of care for severe alcohol withdrawal [abstr]. Critic Care Med. 2012 Dec. 40(12):doi: 10.1097/01.ccm.0000424341.32883.e7.
Linn DD, Loeser KC. Dexmedetomidine for Alcohol Withdrawal Syndrome. Ann Pharmacother. 2015 Dec. 49 (12):1336-42. [Medline].
Minozzi S, Amato L, Vecchi S, Davoli M. Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev. 2010. (3):CD005064. [Medline].
Mayo-Smith MF, Beecher LH, Fischer TL, et al. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med. 2004 Jul 12. 164(13):1405-12. [Medline].
Jaeger TM, Lohr RH, Pankratz VS. Symptom-triggered therapy for alcohol withdrawal syndrome in medical inpatients. Mayo Clin Proc. 2001 Jul. 76(7):695-701. [Medline].
Muzyk AJ, Leung JG, Nelson S, Embury ER, Jones SR. The role of diazepam loading for the treatment of alcohol withdrawal syndrome in hospitalized patients. Am J Addict. 2013 Mar. 22(2):113-8. [Medline].